How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
46
ANTX Quote, Financials, Valuation and Earnings
Last price:
$1.39
Seasonality move
:
-47.68%
Day range:
$1.34 - $1.41
52-week range:
$0.87 - $22.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.47x
Volume:
88.7K
Avg. volume:
796.2K
1-year change:
-93.38%
Market cap:
$41.2M
Revenue:
--
EPS (TTM):
-$2.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ANTX
AN2 Therapeutics
|
-- | -$0.39 | -- | -42.31% | -- |
|
ABUS
Arbutus Biopharma
|
$1.9M | -$0.09 | -26.14% | -31.34% | -- |
|
BMRN
Biomarin Pharmaceutical
|
$703.3M | $0.79 | 10.19% | 566.24% | $98.08 |
|
CDTX
Cidara Therapeutics
|
$433.3K | -$5.44 | -99.31% | -540.11% | -- |
|
FGEN
FibroGen
|
$34.8M | -$0.38 | -1.52% | -64.91% | $10.00 |
|
GLYC
GlycoMimetics
|
-- | -$0.15 | -100% | -35.71% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ANTX
AN2 Therapeutics
|
$1.38 | -- | $41.2M | -- | $0.00 | 0% | -- |
|
ABUS
Arbutus Biopharma
|
$3.19 | -- | $604.5M | -- | $0.00 | 0% | 85.32x |
|
BMRN
Biomarin Pharmaceutical
|
$67.02 | $98.08 | $12.8B | 40.13x | $0.00 | 0% | 4.78x |
|
CDTX
Cidara Therapeutics
|
$23.43 | -- | $256.3M | -- | $0.00 | 0% | 1.92x |
|
FGEN
FibroGen
|
$0.50 | $10.00 | $50.2M | -- | $0.00 | 0% | 0.28x |
|
GLYC
GlycoMimetics
|
$0.24 | -- | $15.6M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ANTX
AN2 Therapeutics
|
-- | 1.207 | -- | -- |
|
ABUS
Arbutus Biopharma
|
-- | 0.487 | -- | 6.84x |
|
BMRN
Biomarin Pharmaceutical
|
9.9% | 0.942 | 4.44% | 2.39x |
|
CDTX
Cidara Therapeutics
|
-- | 4.915 | -- | 4.21x |
|
FGEN
FibroGen
|
-42.59% | 7.090 | 88.52% | 1.13x |
|
GLYC
GlycoMimetics
|
-- | -4.262 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ANTX
AN2 Therapeutics
|
-- | -$11.8M | -- | -- | -- | -$12M |
|
ABUS
Arbutus Biopharma
|
-- | -$17.5M | -67.36% | -67.36% | -1470.35% | -$20.7M |
|
BMRN
Biomarin Pharmaceutical
|
$557.3M | $113.9M | 5.27% | 6.29% | 18.43% | $200.3M |
|
CDTX
Cidara Therapeutics
|
$6.9M | -$17.4M | -443.37% | -443.37% | -3675.83% | -$36.8M |
|
FGEN
FibroGen
|
$41M | $1.8M | -- | -- | -28.01% | -$8.5M |
|
GLYC
GlycoMimetics
|
-- | -$5.7M | -- | -- | -- | -$8M |
AN2 Therapeutics vs. Competitors
-
Which has Higher Returns ANTX or ABUS?
Arbutus Biopharma has a net margin of -- compared to AN2 Therapeutics's net margin of -1472.52%. AN2 Therapeutics's return on equity of -- beat Arbutus Biopharma's return on equity of -67.36%.
Company Gross Margin Earnings Per Share Invested Capital ANTXAN2 Therapeutics-- -$0.43 -- ABUSArbutus Biopharma-- -$0.10 $106.9M -
What do Analysts Say About ANTX or ABUS?
AN2 Therapeutics has a consensus price target of --, signalling upside risk potential of 93.24%. On the other hand Arbutus Biopharma has an analysts' consensus of -- which suggests that it could grow by 63.41%. Given that AN2 Therapeutics has higher upside potential than Arbutus Biopharma, analysts believe AN2 Therapeutics is more attractive than Arbutus Biopharma.
Company Buy Ratings Hold Ratings Sell Ratings ANTXAN2 Therapeutics0 0 0 ABUSArbutus Biopharma0 0 0 -
Is ANTX or ABUS More Risky?
AN2 Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arbutus Biopharma has a beta of 1.842, suggesting its more volatile than the S&P 500 by 84.177%.
-
Which is a Better Dividend Stock ANTX or ABUS?
AN2 Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arbutus Biopharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AN2 Therapeutics pays -- of its earnings as a dividend. Arbutus Biopharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANTX or ABUS?
AN2 Therapeutics quarterly revenues are --, which are smaller than Arbutus Biopharma quarterly revenues of $1.3M. AN2 Therapeutics's net income of -$12.7M is higher than Arbutus Biopharma's net income of -$19.7M. Notably, AN2 Therapeutics's price-to-earnings ratio is -- while Arbutus Biopharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AN2 Therapeutics is -- versus 85.32x for Arbutus Biopharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANTXAN2 Therapeutics-- -- -- -$12.7M ABUSArbutus Biopharma85.32x -- $1.3M -$19.7M
-
Which has Higher Returns ANTX or BMRN?
Biomarin Pharmaceutical has a net margin of -- compared to AN2 Therapeutics's net margin of 14.23%. AN2 Therapeutics's return on equity of -- beat Biomarin Pharmaceutical's return on equity of 6.29%.
Company Gross Margin Earnings Per Share Invested Capital ANTXAN2 Therapeutics-- -$0.43 -- BMRNBiomarin Pharmaceutical74.73% $0.55 $6B -
What do Analysts Say About ANTX or BMRN?
AN2 Therapeutics has a consensus price target of --, signalling upside risk potential of 93.24%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.08 which suggests that it could grow by 46.34%. Given that AN2 Therapeutics has higher upside potential than Biomarin Pharmaceutical, analysts believe AN2 Therapeutics is more attractive than Biomarin Pharmaceutical.
Company Buy Ratings Hold Ratings Sell Ratings ANTXAN2 Therapeutics0 0 0 BMRNBiomarin Pharmaceutical13 5 0 -
Is ANTX or BMRN More Risky?
AN2 Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.295, suggesting its less volatile than the S&P 500 by 70.544%.
-
Which is a Better Dividend Stock ANTX or BMRN?
AN2 Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AN2 Therapeutics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANTX or BMRN?
AN2 Therapeutics quarterly revenues are --, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. AN2 Therapeutics's net income of -$12.7M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, AN2 Therapeutics's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 40.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AN2 Therapeutics is -- versus 4.78x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANTXAN2 Therapeutics-- -- -- -$12.7M BMRNBiomarin Pharmaceutical4.78x 40.13x $745.7M $106.1M
-
Which has Higher Returns ANTX or CDTX?
Cidara Therapeutics has a net margin of -- compared to AN2 Therapeutics's net margin of -30201.66%. AN2 Therapeutics's return on equity of -- beat Cidara Therapeutics's return on equity of -443.37%.
Company Gross Margin Earnings Per Share Invested Capital ANTXAN2 Therapeutics-- -$0.43 -- CDTXCidara Therapeutics81.53% -$2.45 $130.9M -
What do Analysts Say About ANTX or CDTX?
AN2 Therapeutics has a consensus price target of --, signalling upside risk potential of 93.24%. On the other hand Cidara Therapeutics has an analysts' consensus of -- which suggests that it could grow by 23.77%. Given that AN2 Therapeutics has higher upside potential than Cidara Therapeutics, analysts believe AN2 Therapeutics is more attractive than Cidara Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ANTXAN2 Therapeutics0 0 0 CDTXCidara Therapeutics0 0 0 -
Is ANTX or CDTX More Risky?
AN2 Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cidara Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.883%.
-
Which is a Better Dividend Stock ANTX or CDTX?
AN2 Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AN2 Therapeutics pays -- of its earnings as a dividend. Cidara Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANTX or CDTX?
AN2 Therapeutics quarterly revenues are --, which are smaller than Cidara Therapeutics quarterly revenues of $302K. AN2 Therapeutics's net income of -$12.7M is higher than Cidara Therapeutics's net income of -$16M. Notably, AN2 Therapeutics's price-to-earnings ratio is -- while Cidara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AN2 Therapeutics is -- versus 1.92x for Cidara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANTXAN2 Therapeutics-- -- -- -$12.7M CDTXCidara Therapeutics1.92x -- $302K -$16M
-
Which has Higher Returns ANTX or FGEN?
FibroGen has a net margin of -- compared to AN2 Therapeutics's net margin of -36.87%. AN2 Therapeutics's return on equity of -- beat FibroGen's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ANTXAN2 Therapeutics-- -$0.43 -- FGENFibroGen88.57% -$0.17 -$128.9M -
What do Analysts Say About ANTX or FGEN?
AN2 Therapeutics has a consensus price target of --, signalling upside risk potential of 93.24%. On the other hand FibroGen has an analysts' consensus of $10.00 which suggests that it could grow by 1905.62%. Given that FibroGen has higher upside potential than AN2 Therapeutics, analysts believe FibroGen is more attractive than AN2 Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ANTXAN2 Therapeutics0 0 0 FGENFibroGen0 1 0 -
Is ANTX or FGEN More Risky?
AN2 Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison FibroGen has a beta of 0.823, suggesting its less volatile than the S&P 500 by 17.658%.
-
Which is a Better Dividend Stock ANTX or FGEN?
AN2 Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FibroGen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AN2 Therapeutics pays -- of its earnings as a dividend. FibroGen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANTX or FGEN?
AN2 Therapeutics quarterly revenues are --, which are smaller than FibroGen quarterly revenues of $46.3M. AN2 Therapeutics's net income of -$12.7M is higher than FibroGen's net income of -$17.1M. Notably, AN2 Therapeutics's price-to-earnings ratio is -- while FibroGen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AN2 Therapeutics is -- versus 0.28x for FibroGen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANTXAN2 Therapeutics-- -- -- -$12.7M FGENFibroGen0.28x -- $46.3M -$17.1M
-
Which has Higher Returns ANTX or GLYC?
GlycoMimetics has a net margin of -- compared to AN2 Therapeutics's net margin of --. AN2 Therapeutics's return on equity of -- beat GlycoMimetics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ANTXAN2 Therapeutics-- -$0.43 -- GLYCGlycoMimetics-- -$0.15 -- -
What do Analysts Say About ANTX or GLYC?
AN2 Therapeutics has a consensus price target of --, signalling upside risk potential of 93.24%. On the other hand GlycoMimetics has an analysts' consensus of -- which suggests that it could grow by 313.22%. Given that GlycoMimetics has higher upside potential than AN2 Therapeutics, analysts believe GlycoMimetics is more attractive than AN2 Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings ANTXAN2 Therapeutics0 0 0 GLYCGlycoMimetics0 0 0 -
Is ANTX or GLYC More Risky?
AN2 Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GlycoMimetics has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.069%.
-
Which is a Better Dividend Stock ANTX or GLYC?
AN2 Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlycoMimetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AN2 Therapeutics pays -- of its earnings as a dividend. GlycoMimetics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANTX or GLYC?
AN2 Therapeutics quarterly revenues are --, which are smaller than GlycoMimetics quarterly revenues of --. AN2 Therapeutics's net income of -$12.7M is lower than GlycoMimetics's net income of -$9.8M. Notably, AN2 Therapeutics's price-to-earnings ratio is -- while GlycoMimetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AN2 Therapeutics is -- versus -- for GlycoMimetics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANTXAN2 Therapeutics-- -- -- -$12.7M GLYCGlycoMimetics-- -- -- -$9.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 27
Quantum [QMCO] is up 49.62% over the past day.
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
